GERMANTOWN, Md., Oct. 31, 2019 /PRNewswire/ -- Seneca
Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical
company developing novel treatments for diseases of unmet medical
need, will begin trading on the Nasdaq Capital Market under the
ticker symbol, NASDAQ: SNCA beginning on November 1, 2019.
About Seneca Biopharma
Seneca Biopharma, Inc., is a
clinical-stage biopharmaceutical company developing novel
treatments for diseases of unmet medical need. Seneca is in the process of finding and
acquiring new assets, promising sciences and technologies that will
provide meaningful therapies for patients.
Seneca recently entered into a
non-binding term sheet whereby Seneca and Jiangsu QYuns Therapeutics Co.,
Ltd. will enter into a royalty- and milestone-free, perpetual,
non-cancelable, exclusive worldwide, other than in Greater China (which includes Hong Kong, Macau and Taiwan and certain other Asian territories)
license to develop and commercialize certain of QYuns' assets,
including QX005N, targeting IL-4Rα, QX002N, targeting IL-17A,
QX004N targeting IL-23A, and QX006N targeting IFNRα. As
contemplated by the term sheet, Seneca will also gain access to future
antibody assets developed by QYuns and the parties will collaborate
on future pipeline expansion. Upon entering into the license,
Seneca's lead asset will be SNC005
(QX005N) that targets IL-4Rα for the treatment of Asthma and Atopic
Dermatitis.
Cautionary Statement Regarding Forward Looking
Information
This news release contains "forward-looking
statements" made pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as "expect," "anticipate,"
"intend," "plan," "believe," "seek" or "will." Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem's
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2018 filed
with the Securities and Exchange Commission (SEC), and in other
reports filed with the SEC. We do not assume any obligation to
update any forward-looking statements.
Contact:
Josh Barer
Hibiscus BioVentures
josh@hibiscusbio.com
View original
content:http://www.prnewswire.com/news-releases/seneca-biopharma-to-begin-trading-under-new-ticker-symbol-snca-300948840.html
SOURCE Seneca Biopharma, Inc.